Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren's syndrome.

Estelle GerossierSaba NayarSylvie FroidevauxCharlotte G SmithCeline RunserValentina IannizzottoEnrico VezzaliGabin PierlotUlrich MentzelMark J MurphyMarianne M MartinicFrancesca Barone

Published in: Arthritis research & therapy (2021)

Taken together, these results suggest that cenerimod can reduce the overall autoimmune response and improve clinical parameters in the salivary glands in models of Sjögren's syndrome and consequently may reduce histological and clinical parameters associated with the disease in patients.

Keyphrases

end stage renal disease
newly diagnosed
case report
multiple sclerosis
disease activity
prognostic factors
rheumatoid arthritis
patient reported outcomes
metabolic syndrome
glycemic control